Novel Compounds in the Treatment of Schizophrenia-A Selective Review.

Brain Sci · 2023 · PMC10452918 · PMID 37626549

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

A nominally significant improvement in MMN was observed, suggesting that luvadaxistat 50 mg (vs. 500 mg) can improve this illness-related circuitry biomarker at doses associated with partial DAAO inhibition [ 116 ].

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.